0:30:10 · Doug Schinkle, UBS · CEO strategy
How is the new CEO balancing Danaher's operational legacy against the need to change the playbook?
She will keep the operating company structure, talent and business system, while becoming a more connected Danaher with unambiguous share gain as the report card. — Julie Sawyer Montgomery
0:34:27 · Doug Schinkle, UBS · Commercial priorities
Which priority matters most over the next 12 to 18 months and what metrics should investors watch?
Commercial excellence is the nearest-term priority, with higher profitable core growth and share gain as the measures. — Julie Sawyer Montgomery
0:37:13 · Vijay Kumar, Evercore ISI · Bioprocessing outlook
Should bioprocessing grow at very high single digits or low double digits in 2027?
Orders support improving growth rates in 2027, but formal guidance waits until after Q4 planning, and the long-term view stays at high single digits. — Matt Guggeno, Julie Sawyer Montgomery
0:40:40 · Vijay Kumar, Evercore ISI · M&A strategy
How does the CEO view M&A priorities and does Masimo signal a medtech tilt?
M&A remains the capital allocation bias, but Masimo is seen as a continuous diagnostic that compounds with diagnostics, with no medtech bias. — Julie Sawyer Montgomery
0:42:39 · Tycho Peterson, Jefferies · 2027 outlook
Why is 2027 core growth excluding respiratory only 4% to 5%, and is something being left out?
It matches recent quarters and current market conditions, and a quantitative outlook will follow in January after Q4 planning. — Julie Sawyer Montgomery
0:43:38 · Tycho Peterson, Jefferies · Respiratory
Why cut respiratory again, and is $1.5 billion the right base for 2027?
Management plans for a typical flu season at $1.5 billion for 2026 and 2027, noting seasonal swings could move it by a couple hundred million dollars. — Julie Sawyer Montgomery
0:45:43 · Jack Meehan, Seaport Research · AI strategy
How does the CEO view AI's implications for Danaher and its internal deployment?
AI-driven drug discovery is a major long-term opportunity, with Danaher holding instruments, consumables, automation, software and scale, and AI is paired with DBS internally. — Julie Sawyer Montgomery
0:48:48 · Jack Meehan, Seaport Research · Autonomous lab
What is the broader strategy behind the autonomous lab and the NVIDIA announcement?
The goal is to connect AI to physical experiments, proving it inside Danaher first, then working with customers and with NVIDIA and Anthropic. — Julie Sawyer Montgomery
0:51:42 · Scott Davis, Melius Research · Commercial execution
What are the first steps to improve commercial execution, such as compensation or people changes?
She is standardizing sales expectations through DBS and using AI for coaching, and incentives are protected so connected selling never hurts anyone's pay. — Julie Sawyer Montgomery
0:54:15 · Scott Davis, Melius Research · M&A process
How will M&A processes change to raise hit rates without freezing deal-making?
Danaher will keep doing deals but focus on strategically compounding M&A with robust returns, having learned from past misses. — Julie Sawyer Montgomery
0:56:15 · Casey Woodring, JPMorgan · Masimo
How is Masimo trending and how should we think about its contribution next year?
Masimo grew high single digits in its first full quarter, integration is going well, and a healthy funnel of commercial synergies remains. — Julie Sawyer Montgomery
0:58:14 · Casey Woodring, JPMorgan · Bioprocessing orders
What is behind bioprocessing equipment orders, and how will reshoring contribute in 2027?
Equipment orders are in a strong double-digit range, while reshoring is mostly brownfield now, with greenfield impact mostly from 2028. — Matt Guggeno, Julie Sawyer Montgomery
1:00:12 · Evie Kozlowski, Goldman Sachs · Life sciences markets
Where are life sciences end markets in their recovery and where could upside come from?
Pharma and biopharma are robust, biotech funding is reading through, academic is improving modestly from low levels, and early AI-driven workflow demand is showing in automation. — Julie Sawyer Montgomery